Feature Channels:

Pharmaceuticals

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

small molecule drugs, ONC201, Prostate Cancer, Endometrial Cancer, Phase II clinical trials, New Jersey, Rutgers University

‘First in Human’ Trial Defines Safe Dosage for Small Molecule Drug ONC201 for Solid Cancer Tumors

RutgersCancer351.JPG

A ‘first in human’ clinical trial examining the small molecule drug ONC201 in cancer patients with advanced solid tumors shows that this investigational drug is well tolerated at the recommended phase II dose. That’s according to Rutgers Cancer Institute of New Jersey investigators whose research also showed early signs of clinical benefit in patients with advanced prostate and endometrial cancers.

Medicine

Channels:

Caution Needed for Drugs in Development for Most Common Malignant Pediatric Brain Tumor

00191504-003_wm.jpg

Inhibiting the Ezh2 enzyme may be counterproductive for treatment of certain cancers, including the aggressive brain tumor Group 3 medulloblastoma

Medicine

Channels:

New Drug Test Aids Clinicians with Prescription Drug Monitoring in Patients on Chronic Opioids

Drug diversion is a significant contributing factor in prescription pain medication misuse and deadly overdoses. A new oral fluid monitoring test, announced today by Cordant Health Solutions, www.cordantsolutions.com, reports more detailed and actionable information to clinicians than urine drug tests, which can potentially improve therapy adherence, patient safety, and help to identify drug diversion.

Medicine

Channels:

Genetics, Psychiatry, Molecular Biology, Neurobiology, Depression, Mental Health, Pharmaceutical Chemistry, Neuroscience

Mouse Study Identifies New Method for Treating Depression

depression_pixabay.jpg

Standard antidepressant medications don’t work for everyone, and even when they do they are slow to kick in. In an effort to find better depression treatments, researchers at University of California San Diego School of Medicine discovered that inhibiting an enzyme called Glyoxalase 1 (GLO1) relieves signs of depression in mice. Moreover, inhibiting GLO1 worked much faster than the conventional antidepressant Prozac.

Medicine

Channels:

Bioinformatics, Genetics, Cancer, Pharmaceutical Science, Precision Medicine, CRISPR/Cas9

Gene Editing Technique Helps Find Cancer’s Weak Spots

synthetic_lethal_interactions_network_ideker.jpg

Genetic mutations that cause cancer also weaken cancer cells, allowing researchers to develop drugs that will selectively kill them. This is called “synthetic lethality” because the drug is only lethal to mutated (synthetic) cells. Researchers at UC San Diego School of Medicine and Jacobs School of Engineering developed a method to search for synthetic-lethal gene combinations. The technique, published March 20 in Nature Methods, uncovered 120 new opportunities for cancer drug development.

Medicine

Channels:

Researchers Discover Key to Drug Resistance in Common Breast Cancer Treatment

nettles_kendall.jpg

Scientists from the Florida campus of The Scripps Research Institute (TSRI), the University of California (UC), San Diego and the University of Illinois have found that two immune system molecules may be key to the development of drug resistance in estrogen-driven breast cancers.

Medicine

Channels:

pembrolizumab, Mesothelioma, immunotheraphy, Cancer

Pembrolizumab Shows Promise in Treatment of Mesothelioma

Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania. The study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.

Science

Channels:

Chemistry/Physics/Materials Sciences (Biochemistry, Pharmaceutical Sciences); Biology (Biochemistry); Medicine/Health (Neurobiology, Pharmaceutical Science)

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 2-Apr-2017 5:00 AM EDT

Medicine

Channels:

Penn Medicine, Perelman School of Medicine at the University of Pennsylvania, Cardiovascular Medicine, Pulmonary Embolism

High-Risk Pulmonary Embolism Patients Often Go Without Most Effective Treatments

A typical intervention for PE patients includes anticoagulants in an effort to prevent migration of the blood clot, but the higher-risk PE population – about 30 percent of all PE patients – are potential candidates for catheter-directed thrombolysis (CDT) and systemic thrombolysis (ST), both of which employ “clot-busting” medications known as tissue plasminogen activator (tPA). However, in a new study presented today at the American College of Cardiology 66th Annual Scientific Session, researchers from the Perelman School of Medicine at the University of Pennsylvania have found that the utilization rates of these potentially life-saving medications are low, particularly in the sub-group of PE patients who are critically ill.

Medicine

Channels:

Blood Clots, Blood Thinners, Rivaroxaban, Venous Thromboembolism

New Blood Thinner Better at Preventing Recurrent Blood Clots Than Aspirin

VenousthromboembolismlegexamCreditTheOttawaHospital.jpg

Venous thromboembolism is a chronic disease, with risks of additional blood clots over a patient’s lifetime. However, many physicians and patients are deciding against long-term treatment with blood thinners because of concern about the risk of bleeding. Some are choosing aspirin instead because they consider it to be safer. This study has shown that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of life-threatening blood clots in the legs and lungs.







Chat now!